These results suggested that targeting TAMs with anti-siglec15 antibodies conjugated toxins might be a promising anti-tumor therapeutic strategy to decrease the population of TAMs or transform of TAMs into M1 proinflammatory macrophages. Here, SIGLEC15 is linked to neoplasm.